Walgreens and Verily to collaborate on new chronic disease solutions

21 December 2018 (Last Updated December 21st, 2018 10:57)

Walgreens Boots Alliance and Verily have announced collaboration on several projects with the goal of boosting health outcomes and reducing the cost of care for patients suffering with chronic conditions.

Walgreens Boots Alliance and Verily have announced collaboration on several projects with the goal of boosting health outcomes and reducing the cost of care for patients suffering with chronic conditions.

The two firms will work on and explore ways to boost access to advanced healthcare technologies and solutions, which may include sensors and software in the prevention, management, screening and diagnosing of disease.

These solutions will be deployed at Walgreens retail locations.

The companies will initially focus on developing a medication adherence pilot project to deploy devices and other approaches aimed at improving adherence.

Walgreens Boots Alliance CEO Stefano Pessina said: “We’re focused on finding innovative ways to deliver better patient care at lower costs, and working with the right healthcare partners to help bring new services and solutions to our patients and customers.

“The continued rise in chronic diseases today can be costly to patients as well as to our healthcare system. Working with Verily, we’ll look at how we can best support integrated and value-based care to meet our patients’ needs, as well as opportunities to address other chronic conditions over time.”

“We’re focused on finding innovative ways to deliver better patient care at lower costs, and working with the right healthcare partners.”

Verily CEO Andrew Conrad said: “We are well aligned with Walgreens on the need to develop and bring to market solutions that help people better engage with their health and manage their chronic conditions. This relationship affords us the opportunity to jointly tackle real-world issues that significantly impact the health of individuals and communities.

“Medication adherence, which represents one of the most significant and costly barriers to improving patient outcomes, is an area that I am most excited to work on with a partner like Walgreens.”

Walgreens will also introduce a virtual diabetes solution to its employees and family members suffering from Type 2 diabetes along with Onduo, the joint venture company between Verily and Sanofi.

Onduo offers tools, coaching and remote access to physicians so that they can help people suffering with diabetes to manage their condition.

These initiatives are part of a broader strategic alliance intended to bring Verily’s healthcare technology innovation with Walgreens store presence.

Walgreens Boots Alliance is a retail pharmacy chain with more than 18,500 stores in 11 countries. It also has pharmaceutical wholesale and distribution networks, with over 390 distribution centres delivering to over 230,000 pharmacies, doctors, health centers and hospitals annually in over 20 countries.

This JV will study the health and financial impacts of undiagnosed and untreated sleep apnea, and develop software solutions to identify, diagnose, treat and manage individuals with sleep apnea and other breathing-related sleep disorders.